Historical Context & Motivation
The phenomenon of exaggerated immune responses to otherwise harmless substances has been documented for millennia, though systematic understanding only emerged in the late nineteenth and early twentieth centuries. Ancient Egyptian records describe the death of Pharaoh Menes around 2641 BCE, allegedly from a wasp sting—possibly the first recorded case of anaphylaxis. The term "allergy" itself was not coined until 1906, when Viennese pediatrician Clemens von Pirquet observed that some patients reacted to serum therapy in a manner opposite to the intended protective response. These observations laid the groundwork for immunology as a discipline and, critically, for the prehospital emergency protocols that Advanced Emergency Medical Technicians (AEMTs) rely on today. Understanding the historical evolution of allergy science helps contextualize why rapid field identification of allergic reactions and anaphylaxis remains one of the most time-sensitive interventions in the AEMT scope of practice.
Despite these advances, anaphylaxis continues to cause preventable deaths in and out of hospital settings, primarily because of delayed recognition and treatment. The central question for every AEMT remains: how do you rapidly differentiate a localized allergic reaction from a systemic, life-threatening anaphylactic event, and what interventions must be initiated immediately in the field to prevent cardiovascular collapse and airway compromise?
Core Principles & Definitions
At the molecular level, an allergic reaction represents a misdirected immune response in which the body's defenses attack a typically harmless substance known as an allergen. The process begins with an initial exposure that primes the immune system—a phase called sensitization—during which allergen-specific immunoglobulin E (IgE) antibodies are produced and attach to the surface of mast cells and basophils. Upon subsequent re-exposure, the allergen cross-links these surface-bound IgE molecules, triggering rapid degranulation—a massive release of chemical mediators including histamine, leukotrienes, and prostaglandins. These mediators produce the clinical signs AEMTs must recognize: vasodilation, increased vascular permeability, bronchoconstriction, and mucous hypersecretion.
Allergen & Sensitization
Mast Cell Degranulation
Localized vs. Systemic Reactions
Anaphylaxis Criteria
Biphasic Reactions
Visual Explanation — The Anaphylaxis Cascade
The cascade depicted above underscores the speed and systemic nature of anaphylaxis. From the moment an allergen cross-links IgE on mast cell surfaces, the pathophysiological clock begins ticking in seconds rather than minutes. Histamine acts almost instantaneously on H₁ and H₂ receptors throughout the body, producing vasodilation in the peripheral vasculature, bronchoconstriction in the lower airways, and increased capillary permeability that allows plasma to shift from the intravascular compartment into interstitial spaces. This plasma shift is what produces both the visible swelling (angioedema) and the critically dangerous distributive shock—relative hypovolemia despite no actual blood loss. As an AEMT, you should internalize that any combination of two or more organ system involvement following known or suspected allergen exposure constitutes anaphylaxis and demands immediate epinephrine administration.
Pharmacological Mechanism — Epinephrine & Adjunct Therapies
Epinephrine is the cornerstone of anaphylaxis treatment because it directly opposes every major pathophysiological mechanism of the reaction. Its pharmacological action is mediated through adrenergic receptor subtypes, and understanding these receptors explains why no other single medication can replace it in the acute setting. At the AEMT level, you are authorized to administer epinephrine via intramuscular injection and, depending on local protocol, to assist with auto-injector use for patients who carry their own devices.
Adrenergic Receptor Actions of Epinephrine
| Receptor | Location | Epinephrine Effect | Clinical Benefit |
|---|---|---|---|
| Alpha-1 (α₁) | Peripheral vasculature | Vasoconstriction | ↑ SVR, ↑ BP, ↓ mucosal edema, ↓ urticaria |
| Beta-1 (β₁) | Myocardium | ↑ Heart rate, ↑ contractility | ↑ Cardiac output to counteract shock |
| Beta-2 (β₂) | Bronchial smooth muscle | Bronchodilation | Reverses bronchoconstriction, ↓ wheezing |
| Beta-2 (β₂) | Mast cells | ↑ cAMP → inhibits degranulation | Slows further mediator release |
AEMT Dosing Protocols
Adjunct Medications
While epinephrine remains the only first-line agent, several adjunct medications may be administered within the AEMT scope of practice (protocol-dependent). Diphenhydramine (Benadryl, 25–50 mg IV/IM) is an H₁-receptor antagonist that reduces urticaria and pruritus but does not reverse bronchospasm or hypotension and should never delay epinephrine. Albuterol (2.5 mg nebulized) serves as a β₂-selective bronchodilator for persistent wheezing after epinephrine. Normal saline bolus (1–2 L for adults) addresses hypovolemia from third-spacing. Critically, none of these adjuncts replace epinephrine—they are supportive measures only.
Detailed Assessment & Classification
Accurate field assessment is the bridge between pathophysiology knowledge and life-saving intervention. The AEMT must systematically evaluate the patient using a structured approach that integrates history of present illness, physical examination findings, and vital sign trends. The severity classification system below guides treatment decisions and transport priority, helping you communicate clearly with receiving facilities and medical direction.
SAMPLE & OPQRST in Allergic Reactions
During the focused history, utilize the SAMPLE mnemonic to gather critical data: Signs/Symptoms (onset, progression, and organ systems involved), Allergies (the specific trigger, prior reaction severity, and history of anaphylaxis), Medications (current prescriptions, especially beta-blockers which can make anaphylaxis refractory to epinephrine), Past medical history (asthma, atopy, prior anaphylaxis), Last oral intake (relevant if food-triggered), and Events leading to the present illness. Supplement this with OPQRST to characterize any associated pain or discomfort. Pay particular attention to patients on beta-blockers, as these medications blunt the compensatory tachycardia response and may render standard epinephrine doses less effective, potentially necessitating glucagon administration at the hospital level.
Worked Example — Prehospital Anaphylaxis Management
Common Allergen Categories & Differential Diagnosis
A thorough understanding of common allergen categories helps the AEMT anticipate the severity and progression of reactions. Additionally, several conditions mimic anaphylaxis and must be considered during differential diagnosis to avoid both under-treatment and over-treatment. The tables below organize this information for rapid clinical reference.
| Allergen Category | Common Examples | Typical Route | Onset Speed | Severity Risk |
|---|---|---|---|---|
| Insect Venoms | Bee, wasp, hornet, fire ant | Injection (sting) | 5−15 minutes | High — rapid systemic spread |
| Foods | Peanuts, tree nuts, shellfish, eggs, milk | Ingestion | 5−30 minutes | High — most common cause of fatal anaphylaxis |
| Medications | Penicillin, sulfa drugs, NSAIDs, aspirin | Oral / IV / IM | Seconds (IV) to 30 min (oral) | Very high for IV medications |
| Latex | Gloves, catheters, balloons | Contact / mucosal | Minutes to hours | Moderate — healthcare workers at increased risk |
| Environmental | Pollen, mold, animal dander, dust mites | Inhalation | Minutes | Low — typically localized (rhinitis, asthma) |
Differential Diagnosis: Conditions That Mimic Anaphylaxis
| Condition | Key Differentiating Features |
|---|---|
| Vasovagal syncope | Bradycardia (not tachycardia), pallor (not flushing), no urticaria, rapid recovery when supine |
| Asthma exacerbation | Isolated bronchospasm without skin findings, hypotension, or GI symptoms; history of asthma |
| Panic / anxiety attack | Hyperventilation, tingling extremities, no urticaria or hypotension, normal SpO₂ |
| Angioedema (ACE-inhibitor) | Facial/tongue swelling without urticaria; bradykinin-mediated (not histamine); does NOT respond to epinephrine |
| Septic shock | Hypotension and tachycardia present, but gradual onset over hours with fever; no urticaria |
Connection to Advanced Theory — Anaphylactoid Reactions & Paramedic-Level Care
As AEMTs progress toward paramedic-level practice, several advanced concepts expand on the foundational knowledge of allergic reactions and anaphylaxis. Understanding these concepts now strengthens clinical reasoning and prepares you for expanded scope interventions. The distinction between true anaphylaxis and anaphylactoid reactions is clinically significant: anaphylactoid reactions produce identical signs and symptoms but occur without prior sensitization and are not IgE-mediated. Radiocontrast media, opioids, and vancomycin can trigger direct mast cell degranulation on first exposure, bypassing the sensitization phase entirely. Despite the different mechanism, prehospital treatment is identical—epinephrine remains the first-line intervention because the downstream pathophysiology is the same.
| Feature | AEMT Scope | Paramedic Scope |
|---|---|---|
| Epinephrine Route | IM only (auto-injector or ampule) | IM and IV push / IV infusion (1:10,000 for IV) |
| Airway Management | BLS airway adjuncts, supraglottic devices | Rapid sequence intubation, surgical cricothyrotomy |
| Vasopressors | Not in scope | Epinephrine drip, norepinephrine, vasopressin for refractory shock |
| Corticosteroids | Generally not in scope | Methylprednisolone / dexamethasone IV for biphasic prevention |
| Glucagon | Not in scope | 1−5 mg IV for beta-blocker-refractory anaphylaxis |
| Cardiac Monitoring | Pulse oximetry, vital signs | 12-lead ECG, continuous cardiac monitoring, capnography |
It is also important for the AEMT to understand the concept of refractory anaphylaxis—cases in which the patient fails to respond to repeated IM epinephrine doses. Risk factors include delayed treatment, concurrent beta-blocker use, massive allergen exposure, and mast cell disorders such as mastocytosis. When you encounter a patient who does not improve after two IM epinephrine doses, communicate this urgently to medical direction and the receiving facility, as these patients will likely require IV epinephrine infusion and advanced airway management. Your early recognition and clear communication can save critical minutes in the chain of care.
Practice Problems
Summary — Allergic Reactions and Anaphylaxis
Allergic reactions represent a spectrum of immune-mediated responses ranging from localized urticaria and pruritus to life-threatening anaphylaxis. The underlying mechanism involves IgE-mediated sensitization during initial allergen exposure, followed by explosive mast cell degranulation upon re-exposure, releasing histamine, leukotrienes, and prostaglandins that produce vasodilation, bronchoconstriction, increased vascular permeability, and distributive shock. Anaphylaxis is diagnosed clinically by the presence of two or more organ systems involved after known or suspected allergen exposure, particularly the combination of skin/mucosal findings with respiratory compromise or hypotension.
For the AEMT, the definitive first-line treatment is intramuscular epinephrine (0.3−0.5 mg for adults, 0.01 mg/kg for pediatrics) administered into the vastus lateralis (lateral thigh). Epinephrine's alpha-1, beta-1, and beta-2 receptor actions counteract every major pathway of the anaphylactic cascade. Adjunct therapies including diphenhydramine, albuterol, oxygen, and IV normal saline support but never replace epinephrine. Patients on beta-blockers may exhibit refractory anaphylaxis. All patients receiving prehospital anaphylaxis treatment require hospital transport for observation due to the risk of biphasic reactions occurring up to 72 hours after the initial event.